Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Vaccines01:21

Vaccines

49
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
49
Viral Mutations00:36

Viral Mutations

40.8K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
40.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HIV-1 BG505 SOSIP immunization induced B cell expansion targeting the 465-glycan hole, with neutralizing antibodies exhibiting distinct binding modes and mechanisms of virus inhibition.

PLoS pathogens·2026
Same author

Coadministration of rapamycin with a DNA/MVA SIV vaccine improves memory CD8+ T cell response.

JCI insight·2026
Same author

Mpox emergence and new vaccines: a story of susceptibility.

Current opinion in immunology·2026
Same author

α4 Integrin blockade impairs CD8+ T cell neuroimmune surveillance following SIV infection.

The Journal of clinical investigation·2026
Same author

Limited Sex-Based Differences in Viral Outcomes of ART-Treated SIV/SHIV Infection.

The Journal of infectious diseases·2026
Same author

Western Diet Dampens T Regulatory Cell Function to Fuel Hepatic Inflammation in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Cells·2026

Related Experiment Video

Updated: Apr 4, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.9K

DNA/MVA Vaccines for HIV/AIDS.

Smita S Iyer1, Rama R Amara2

  • 1Emory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA. siyer3@emory.edu.

Vaccines
|September 8, 2015
PubMed
Summary

DNA vaccines are a safe and effective platform for generating HIV-specific immune responses. Innovations in DNA vaccine technology, including improved delivery and adjuvant co-expression, are advancing clinical applications for HIV vaccines.

Keywords:
CD40LGM-CSFSIVadjuvantrhesus macaque

More Related Videos

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
08:10

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

9.3K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

8.1K

Related Experiment Videos

Last Updated: Apr 4, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.9K
Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
08:10

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

9.3K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

8.1K

Area of Science:

  • Immunology
  • Vaccinology
  • Molecular Biology

Background:

  • DNA vaccines utilize plasmid DNA to elicit immune responses against foreign antigens.
  • Early DNA vaccine studies showed potential but faced challenges with insufficient immune response magnitude.
  • Significant advancements have been made in DNA vaccine technology over the past two decades.

Purpose of the Study:

  • To review preclinical studies of the DNA-prime/modified vaccinia Ankara (MVA)-boost vaccine for Human Immunodeficiency Virus (HIV).
  • To examine strategies for enhancing DNA vaccine immunogenicity, particularly through co-expression of immune modulatory adjuvants.
  • To discuss the progress and potential of DNA-based HIV vaccines in clinical applications.

Main Methods:

  • Review of preclinical research on DNA-prime/MVA-boost vaccination strategies for HIV.
  • Analysis of optimized plasmid constructs and delivery methods like electroporation.
  • Investigation of molecular adjuvants and combination strategies with viral vectors and subunit proteins.

Main Results:

  • DNA vaccines are clinically safe and effective for priming HIV-specific cellular and humoral responses.
  • Optimized constructs, advanced delivery, and adjuvant co-expression enhance DNA vaccine immunogenicity.
  • Preclinical data suggest promising results for DNA-based HIV vaccine candidates.

Conclusions:

  • DNA vaccine technology has evolved significantly, offering a viable platform for HIV vaccine development.
  • Co-expression of immune modulatory adjuvants is a key strategy for boosting DNA vaccine efficacy.
  • Innovations in DNA vaccines are paving the way for their clinical application against HIV.